Clinical Trial Update: Study of Aripiprazole to Reduce Medical Risks in Bipolar Disorder [NA]

View source ↗

Summary

Terminated study evaluating aripiprazole to reduce medical risks in bipolar disorder with metabolic syndrome; results were posted on February 12, 2016.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bipolar Disorder
• Metabolic Syndrome

Drugs mentioned

• ARIPIPRAZOLE (Aripiprazole)

Snippet

Sponsor: University of Pittsburgh | Conditions: Bipolar Disorder, Metabolic Syndrome | NA | Status: TERMINATED | Results posted: 2016-02-12